PILRA

PILRA is an ITIM-bearing inhibitory immunoreceptor expressed on myelomonocytic cells—including monocytes, macrophages, granulocytes, dendritic cells, and microglia—that recruits SHP-1 and SHP-2 phosphatases upon tyrosine phosphorylation to suppress activating immune signals such as calcium mobilization downstream of FcγRII (PMID:10903717). In microglia, PILRA suppresses immunometabolic fitness, lipid storage, mitochondrial bioenergetics, and amyloid clearance through PPAR and STAT1/3 signaling pathways; genetic deletion or antibody-mediated blockade of PILRA in iPSC-derived microglia rescues these deficits, and transplantation of PILRA-knockout human microglia into Alzheimer's disease model mice reduces amyloid pathology and restores synaptic markers (PMID:41337541). PILRA expression is regulated at the translational level by a 5′-end ramp of slowly translated codons, and the synonymous Alzheimer's-protective variant rs2405442:T>C disrupts this ramp to reduce both mRNA and protein levels (PMID:40149715).

1. 2000 High

   Establishing that PILRA is a myeloid-restricted inhibitory receptor resolved the question of whether this orphan Ig-superfamily gene encoded an activating or inhibitory molecule and defined its signaling mechanism through ITIM-mediated SHP-1/SHP-2 recruitment and calcium mobilization suppression.

   Evidence Overexpression in U937 cells, pervanadate-induced co-immunoprecipitation of SHP-1/SHP-2, and cross-linking-based calcium mobilization inhibition assay

   PMID:10903717

   Open questions at the time

   • Endogenous ligand(s) for PILRA were not identified in this study
   • Downstream signaling consequences beyond calcium suppression not explored
   • In vivo functional role in tissue-resident myeloid cells not addressed
2. 2025 High

   Demonstrating that PILRA knockout in human microglia rescues immunometabolic deficits and reduces amyloid pathology in vivo established PILRA as a tonic brake on microglial protective functions relevant to Alzheimer's disease, acting through PPAR and STAT1/3 pathways.

   Evidence PILRA KO in iPSC-derived microglia, chimeric AD mouse transplantation, pharmacological PPAR/STAT1/3 inhibitor studies, metabolic and amyloid quantification, ligand-blocking antibody phenocopy

   PMID:41337541

   Open questions at the time

   • Precise molecular link between ITIM-proximal SHP phosphatase activity and downstream PPAR/STAT1/3 signaling not delineated
   • Contribution of individual ligands to microglial PILRA engagement in the AD brain not resolved
   • Whether PILRA blockade affects non-microglial myeloid populations in the CNS is unknown
3. 2025 Medium

   Identifying a translational ramp mechanism at the PILRA 5′ end explained how the synonymous AD-protective variant rs2405442 reduces PILRA expression independently of the linked missense variant, adding a post-transcriptional regulatory layer to PILRA biology.

   Evidence qPCR and ELISA quantification of wildtype vs. variant PILRA constructs in CHO cells

   PMID:40149715

   Open questions at the time

   • Not yet independently replicated or validated in primary myeloid or microglial cells
   • Whether reduced PILRA protein from this variant is sufficient to alter microglial function in vivo is untested
   • Structural basis for ramp-dependent translational regulation not resolved

• It remains unknown how PILRA's proximal ITIM/SHP signaling mechanistically connects to the PPAR and STAT1/3 pathways that govern its metabolic and inflammatory effects in microglia, and the full repertoire of physiological ligands driving PILRA engagement in healthy and diseased tissues is incompletely defined.
• No reconstituted biochemical pathway from ITIM phosphorylation to PPAR/STAT transcriptional output
• Structural basis for PILRA ligand recognition and selectivity not fully characterized
• Role of PILRA in non-CNS myeloid biology (e.g., infection, autoimmunity) largely unexplored in mechanistic terms